BSE Live
Mar 30, 11:30Prev. Close
1281.95
Open Price
1261.00
Bid Price (Qty.)
1258.30 (2)
Offer Price (Qty.)
1258.95 (45)
NSE Live
Mar 30, 11:30Prev. Close
1281.70
Open Price
1265.00
Bid Price (Qty.)
1258.60 (103)
Offer Price (Qty.)
1258.90 (69)
| Cash Flow of Dr Reddys Laboratories (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| Net Profit/Loss Before Extraordinary Items And Tax | 7,235.90 | 5,791.30 | 3,866.00 | 2,223.80 | 3,056.20 | |
| Net CashFlow From Operating Activities | 4,225.00 | 3,449.70 | 5,052.90 | 1,338.70 | 3,514.20 | |
| Net Cash Used In Investing Activities | -5,697.60 | -3,430.30 | -3,447.60 | -2,038.00 | -1,458.00 | |
| Net Cash Used From Financing Activities | 1,590.70 | 68.10 | -2,696.90 | 505.50 | -794.30 | |
| Foreign Exchange Gains / Losses | 0.20 | 1.60 | 44.50 | 47.90 | 4.40 | |
| Adjustments On Amalgamation Merger Demerger Others | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Inc/Dec In Cash And Cash Equivalents | 118.30 | 89.10 | -1,047.10 | -145.90 | 1,266.30 | |
| Cash And Cash Equivalents Begin of Year | 201.40 | 112.30 | 1,159.40 | 1,305.40 | 39.10 | |
| Cash And Cash Equivalents End Of Year | 319.70 | 201.40 | 112.30 | 1,159.50 | 1,305.40 |
09.03.2026
06.03.2026
06.03.2026
25.02.2026
22.01.2026
Dr Reddys Labs Consolidated December 2025 Net Sales at Rs 8,753.40 crore, up 4.44% Y-o-Y
22.01.2026
Dr Reddys Labs Standalone December 2025 Net Sales at Rs 4,282.70 crore, down 14.6% Y-o-Y
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
28.10.2025
Dr Reddys Labs Consolidated September 2025 Net Sales at Rs 8,828.30 crore, up 9.83% Y-o-Y
22.01.2025
Dr Reddy's Labs Q3 Preview: Lower Revlimid contribution, subdued US sales to dent earnings growth
12.07.2023
Dr Reddys Laboratories Q1 PAT seen up 73.7% YoY to Rs 912.4 cr: Nirmal Bang
24.01.2023
Dr Reddy’s Q3 Preview | Sharp drop in net profit likely on slump in US revenues
27.10.2022
Dr Reddy’s Q2 preview: Pharma major likely to report sharp drop in net profit on weak US biz
30.03.2026
29.03.2026
27.03.2026
After Biologics merger, new CEO Shreehas Tambe recasts Biocon as global medicines player
27.03.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth